Related Experiment Video
Updated: Dec 21, 2025
09:49
Routine Screening Method for Microparticles in Platelet Transfusions
Published on: January 31, 2018
16.4K
Early decrease in blood platelet count is associated with poor prognosis in COVID-19 patients-indications for
Xiaofang Zhao1, Kun Wang1, Peiyuan Zuo2
1Department of Geriatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
The EPMA Journal
|May 19, 2020
Summary
Platelet count changes in COVID-19 patients indicate disease severity. An early decrease in platelet count is linked to higher mortality risk in coronavirus disease 2019 patients.
Area of Science:
- Hematology
- Infectious Diseases
- Critical Care Medicine
Background:
- Platelet count is a sensitive indicator of illness severity in COVID-19.
- Monitoring thrombocyte turnover is clinically useful for patients with aggressive viral infections.
Purpose of the Study:
- To investigate the significance of platelet count during disease progression in COVID-19 patients.
- To analyze the association between platelet count and mortality in COVID-19.
Main Methods:
- A cohort study of 532 COVID-19 patients was conducted.
- Generalized additive models compared platelet count trends in survivors and non-survivors.
- Exclusion criteria included specific comorbidities and data availability.
Main Results:
- The mortality rate was 5.45% (29 deaths).
- Platelets decreased in non-survivors and increased in survivors within one week post-admission.
- The difference in platelet count between groups increased daily by 5.3 × 10^9/L.
Conclusions:
- Platelet count dynamically reflects pathophysiological changes in early-stage COVID-19.
- An early decrease in platelet count is associated with COVID-19 mortality.
- Causality between platelet count and mortality cannot be definitively concluded from this data.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
949
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
949
01:18Structure and Function of Platelets
2.6K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
2.6K
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
02:50Combination Therapies and Personalized Medicine
5.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K